CD7 and acute lymphoblastic leukemia: In T-ALL, clinical trials are also underway to evaluate the safety and efficacy of multiple base-edited allogeneic Anti-CD7 CAR-T cells in relapsed/refractory patients (NCT05885464), or to assess the effect of treatment as a prognostic HDACi Chidamide targeted therapy for adult T-LBL/ALL (NCT03564704).